Xingjuan (Jane) Chao, Ph.D. is a co-founder of our company and has served as a member of our board of directors and as our Chief Executive Officer since October 2015, and as our President since July 2016. Prior to joining Ceribell, Dr. Chao served as Principal Manager of Portfolio Management Strategy at Genentech, Inc., a biotechnology company, from June 2014 until August 2015, and as Senior Strategy Manager at Novartis AG, a pharmaceutical company, from January 2013 until June 2014. Dr. Chao previously served as a management consultant at McKinsey & Company, a consulting company, from July 2007 until January 2013. Dr. Chao has served on the board of directors of Magnus Medical, Inc., a medical equipment company, since November 2021. Dr. Chao received a B.S. in chemistry from Peking University and a Ph.D. in biophysics from Cornell University.

Mat Jachim, VP of Commercial Operations, joined Ceribell in 2022. Throughout his career, Mat has specialized in scaling and operationalizing commercial teams in companies ranging in size from start-ups to Fortune 50 organizations. Prior to joining Ceribell, Mat was the Sr. Director of Commercial Operations at iRhythm Technologies where he successfully implemented strategies to streamline operations, increase sales productivity, and led efforts to provide Cardiac Monitoring in the Primary Care setting. Previously, Mat held positions with Veritas Technologies, Oracle, and Comcast Corp where he held roles in Sales Operations, Marketing Operations and Product Marketing. Mat holds an MBA from Santa Clara University with a specialization in Marketing.

Louisa Daniels has served as General Counsel of Ceribell since August 2023. Ms. Daniels has been practicing law for over 30 years and oversees all legal and compliance matters for Ceribell. Ms. Daniels has a track record of successful execution with both private and public life sciences and technology companies, including in connection with commercial product launches, and resolution of complex litigation, compliance and other corporate matters. Ms. Daniels has worked for several global biopharmaceutical companies in her career. Before Ceribell, Ms. Daniels was Chief Legal Officer and Chief Compliance Officer for Recursion Pharmaceuticals, a clinical-stage company focused on AI-enabled drug discovery, which she helped take public in April 2021. From 2008 to 2021, Ms. Daniels served as Vice President and Assistant General Counsel at Pfizer, where she held various management positions including Chief Counsel for Global Product Development; Global Commercial Operations, Strategy & Portfolio Management; and both BioTherapeutics and PharmaTherapeutics R&D. Prior to Pfizer, she worked as in-house counsel at Elan Pharmaceuticals and Tularik Inc., which was acquired by Amgen during her tenure. Ms. Daniels received a B.A. and J.D. from the University of California, Berkeley and an M.B.A. from the University of California, Irvine (Paul Merage School of Business).